Drug-induced rheumatic diseases: A review of published case reports from the last two years

Current Opinion in Rheumatology

Volumn 24, Issue 2, 2012, Pages 182-186

  Bukhari, Marwan ^a  

^a ROYAL LANCASTER INFIRMARY   (United Kingdom)

Author keywords

case reports; drug induced disease; review

Indexed keywords

INTERFERON; PROPYLTHIOURACIL; TUMOR NECROSIS FACTOR INHIBITOR;

DRUG INDUCED DISEASE; EMBASE; HUMAN; LUPUS VULGARIS; MEDICAL LITERATURE; MEDLINE; MYOSITIS; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; SCLERODERMA; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS;

ANTINEOPLASTIC AGENTS; HUMANS; RHEUMATIC DISEASES;

EID: 84856937131     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32835059cd     Document Type: Review

References (52)

1. Rizvi R, Hojjati M. Interferon-A induced lupus in a patient with chronic hepatitis C virus. J Clin Rheumatol 2011; 17:152-153. This was a case in which lupus was induced by interferon-Alpha in a patient with chronic hepatitis C.
2. Onishi S, Nagashima T, Kimura H, et al Systemic lupus erythematosus and Sjögren's syndrome induced in a case by interferon-Alpha used for the treatment of hepatitis C. Lupus 2010 19 753-755. This was a patient who satisfied criteria for both Sjogren's syndrome and lupus after treatment of hepatitis C with interferon alpha. 3. Sladkova V, Mares J, Lubenova B, et al. Drug-induced systemic lupus erythematosus in interferon beta-1b therapy. Neuro Endocrinol Lett 2011; 32:4-6. This was a case of interferon beta given to a patient with multiple sclerosis who then developed drug-induced lupus.
3. Funke AA, Kulp-Shorten CL, Callen JP. Subacute cutaneous lupus erythematosus exacerbated or induced by chemotherapy. Arch Dermatol 2010; 146:1113-1116.
4. Navarro NL, Domínguez EG, Acosta EH, et al. Occurrence of subacute cutaneous lupus erythematosus after treatment with systemic fluorouracil. J Clin Oncol 2011; 29:e613-e615.
5. Defelice T, Lu P, Loyd A, et al. Livedo racemosa, secondary to drug-induced systemic lupus erythematosus. Dermatol Online J 2010; 16:24.
6. Mendese G, Demierre MF. Systemic lupus erythematosus induced by cefepime. J Am Acad Dermatol 2011; 64:e37.
7. Yokoyama T, Usui T, Kiyama K, et al. Two cases of late-onset drug-induced lupus erythematosus caused by ticlopidine in elderly men. Mod Rheumatol 2010; 20:405-409.
8. Parekh K, Ching D, Rahman MU, Stamp LK. Onset of Wegener's granulomatosis during therapy with golimumab for rheumatoid arthritis: A rare adverse event? Rheumatology (Oxford) 2010; 49:1785-1787.
9. Fujikawa K, Kawakami A, Hayashi T, et al. Cutaneous vasculitis induced by TNF inhibitors: A report of three cases. Mod Rheumatol 2010; 20:86-89.
10. Lahita RG, Vernace MA. Vasculitis, vitiligo, thyroiditis, and altered hormone levels after antitumor necrosis factor therapy. J Rheumatol 2011; 38:579-580.
11. Hirohama D, Hoshino J, Hasegawa E, et al. Development of myeloperoxidaseantineutrophil cytoplasmic antibody-Associated renal vasculitis in a patient receiving treatment with antitumor necrosis factor-A. Mod Rheumatol 2010; 20:602-605.
12. Katoh N, Kubota M, Shimojima Y, et al. Takayasu's arteritis in a patient with Crohn's disease: An unexpected association during infliximab therapy. Intern Med 2010; 49:179-182.
13. Asahina A, Ohshima N, Nakayama H, et al. Henoch-Schönlein purpura in a patient with rheumatoid arthritis receiving etanercept. Eur J Dermatol 2010; 20:521-522.
14. Pastore S, Londero M, Gortani G, et al. Infliximab-related vasculitis in patients affected by ulcerative colitis. J Pediatr Gastroenterol Nutr 2010; 51:226-228.
15. Tu YL, Tsai YC, Huang JL, Yao TC. Occult pulmonary hemorrhage as a rare presentation of propylthiouracil-induced vasculitis. Pediatrics 2011; 127:e245-e249.
16. Morais P, Baudrier T, Mota A, et al. Antineutrophil cytoplasmic antibody (ANCA)-positive cutaneous leukocytoclastic vasculitis induced by propylthiouracil confirmed by positive patch test: A case report and review of the literature. Cutan Ocul Toxicol 2011; 30:147-153.
17. Anić B, Baresić M, Cerovec M, et al. Propylthiouracil- induced antineutrophil cytoplasmic antibodies (ANCA) skin vasculitis: The first case reported in Croatia. Acta Dermatovenerol Croat 2010; 18:104-106.
18. Antonucci A, Bardazzi F, Iozzo I, Patrizi A. Necrotizing vasculitis in a patient affected by autoimmune hyperthyroidism treated with propylthiouracil. Dermatol Ther 2010; 23 (Suppl 2):S41-S43.
19. Darné S, Natarajan S, Blasdale C. Do antineutrophil cytoplasmic antibodies (ANCA) play a key role in neutrophilic dermatoses? A case of propylthiouracilinduced neutrophilic dermatosis with positive perinuclear ANCA. Clin Exp Dermatol 2010; 35:406-408.
20. Ahmed K, Rao S, Simha V. Antineutrophil cytoplasmic antibodypositive vasculitis in a patient with graves disease: Cross-reaction between propylthiouracil and methimazole. Endocr Pract 2010; 16:449-451.
21. Jenkins J, Babu K, Hsu-Hung E, et al. ANCA-positive necrotizing vasculitis and thrombotic vasculopathy induced by levamisole-Adulterated cocaine: A distinctive clinicopathologic presentation. J Am Acad Dermatol 2011; 65:e14-e16.
22. Buchanan JA, Vogel JA, Eberhardt AM. Levamisole-induced occlusive necrotizing vasculitis of the ears after use of cocaine contaminated with levamisole. J Med Toxicol 2011; 7:83-84.
23. Lung D, Lynch K, Agrawal S, et al. Images in emergency medicine. Adult female with rash on lower extremities. Vasculopathic purpura and neutropenia caused by levamisole-contaminated cocaine. Ann Emerg Med 2011; 57:307.
24. Uchimiya H, Higashi Y, Kawai K, Kanekura T. Purpuric drug eruption with leukocytoclastic vasculitis due to gefitinib. J Dermatol 2010; 37:562-564. This was a purpuric drug eruption which, when biopsied, was found to contain a leukocytoclastic vasculitis.
25. Ko JH, Shih YC, Hui RC, Yang CH. Necrotizing vasculitis triggered by gefitinib: An unusual clinical presentation. J Clin Oncol 2011; 29:e169-e170. This was a patient who developed cutaneous disease on treatment that was a biopsy proven necrotising vasculitis.
26. Granel B, Rossi P, Koeppel MC, et al. Churg and Strauss vasculitis in the course of masitinib treatment: A first report. Allergy 2010; 65:1059-1060.
27. Pellegrini F, Astorino S, Castaldi N, et al. Small vessel vasculitis related to 5-fluorouracil and folinic acid. Eur J Dermatol 2010; 20:862-863.
28. Ramsay LB, Stany MP, Edison JD, et al. Gemcitabine-Associated large vessel vasculitis presenting as fever of unknown origin. J Clin Rheumatol 2010; 16:181-182.
29. Santoro S, Santini M, Pepe C, et al. Aromatase inhibitor-induced skin adverse reactions: Exemestane-related cutaneous vasculitis. J Eur Acad Dermatol Venereol 2011; 25:596-598; doi: 10.1111/j.1468-3083.2010.03803.x.
30. van den Berg FP, Wagenvoort JH, van der Kleij AM, Teijink JA. Ciprofloxacininduced hemorrhagic vasculitis. Ann Vasc Surg 2010; 24:256. e13-e15.
31. Sen D, Rosenstein ED, Kramer N. ANCA-positive vasculitis associated with simvastatin/ezetimibe: Expanding the spectrum of statin-induced autoimmunity? Int J Rheum Dis 2010; 13:e29-e31.
32. Gnanaraj J, Saif MW. Hypersensitivity vasculitis associated with leuprolide (Lupron). Cutan Ocul Toxicol 2010; 29:224-227.
33. Hughes R, Lacour JP, Baldin B, et al. Urticarial vasculitis secondary to H1N1 vaccination. Acta Derm Venereol 2010; 90:651-652.
34. Ishikawa Y, Yukawa N, Ohmura K, et al. Etanercept-induced anti-Jo-1-Antibody-positive polymyositis in a patient with rheumatoid arthritis: A case report and review of the literature. Clin Rheumatol 2010; 29:563-566. This was a patient with pre-existing antibodies who developed the full-blown myositis syndrome when given etanercept.
35. Klein R, Rosenbach M, Kim EJ, et al. Tumor necrosis factor inhibitorassociated dermatomyositis. Arch Dermatol 2010; 146:780-784.
36. Brunasso AM, Scocco GL, Massone C. Dermatomyositis during adalimumab therapy for rheumatoid arthritis. J Rheumatol 2010; 37:1549-1550.
37. Wagner M, Mühldorfer-Fodor M, Prommersberger KJ, Schmitt R. Statininduced focal myositis of the upper extremity. a report of two cases. Eur J Radiol 2011; 77:258-260.
38. Grable-Esposito P, Katzberg HD, Greenberg SA, et al. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010; 41:185-190.
39. Zaraa IR, Labbéne I, Mrabet D, et al. Simvastatin-induced dermatomyositis in a 50-year-old man. BMJ 2011. doi:10.1136/bcr.02.2011.3832 [Accessed 7 October 2011]
40. Hahn M, Sriharan K, McFarland MS. Gemfibrozil-induced myositis in a patient with normal renal function. Ann Pharmacother 2010; 44:211-214.
41. Kalajian AH, Cely SJ, Malone JC, et al. Hydroxyurea-Associated dermatomyositis-like eruption demonstrating abnormal epidermal p53 expression: A potential premalignant manifestation of chronic hydroxyurea and UV radiation exposure. Arch Dermatol 2010; 146:305-310.
42. Diaz-Sanchez A, Rodriguez-Salas N, Aramendi T, Balbin E. Myositis due to Sorafenib intake in a patient with hepatocellular carcinoma. Dig Liver Dis 2011; 43:333-334.
43. Aouba A, Georgin-Lavialle S, Terrier B, et al. Anti-PL7 antisynthetase syndrome under interferon therapy. Joint Bone Spine 2011; 78:94-97. This was a patient with hepatitis C who developed a well characterised myositis with features consistent with the dermato-myositis, polymyositis and the Pl-7 syndrome on biopsy.
44. Lazúrová I, Angelovicová J, Petríková J, et al. A case of polymyositis and vasculitis induced by ovulation induction therapy with gonadotropin-releasing hormone. Clin Rheumatol 2010; 29:1327-1330.
45. Yang CY, Park SA, Kim HS, Shin YI. Polymyositis in patients taking antiviral clevudine therapy: A report of two cases. NeuroRehabilitation 2010; 26:159-162.
46. Konishi Y, Sato H, Sato N, et al. Scleroderma-like cutaneous lesions induced by paclitaxel and carboplatin for ovarian carcinoma, not a single course of carboplatin, but re-induced and worsened by previously administrated paclitaxel. J Obstet Gynaecol Res 2010; 36:693-696. This was a case of scleroderma occurring then recurring when the chemotherapeutic agents were given, giving stronger evidence for causality.
47. Pedersen JV, Jensen S, Krarup-Hansen A, Riis L. Scleroderma induced by paclitaxel. Acta Oncol 2010; 49:866-868. This was a patient who developed diffuse systemic sclerosis after treatment with no auto-Antibodies detected in the serum but marked skin involvement and Raynaud's phenomena.
48. Mattozzi C, Richetta AG, Cantisani C, et al. Morphea, an unusual side effect of anti-TNF-Alpha treatment. Eur J Dermatol 2010; 20:400-401.
49. Sterba G, Sterba Y, Stempel C, et al. Macrophage activation syndrome induced by etanercept in a patient with systemic sclerosis. Isr Med Assoc J 2010; 12:443-445.
50. Marino D, Malandrini A, Rocchi R, et al. Transient 'sicca syndrome' during phenobarbital treatment. J Neurol Sci 2011; 300 (1-2):164.
51. Yemisci OU, Yalbuzdag SA, Karatas M. Risedronate-induced arthritis. J Clin Rheumatol 2010; 16:168-169.
52. Lyman J, Serebro L. Efalizumab-induced inflammatory polyarthritis: What are the implications? South Med J 2010; 103:357-360.